We are live on ! Find out more
COLL icon

Collegium Pharmaceutical

193 hedge funds and large institutions have $1.24B invested in Collegium Pharmaceutical in 2023 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 58 increasing their positions, 77 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

154% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 13

43% more capital invested

Capital invested by funds: $865M → $1.24B (+$373M)

12.06% more ownership

Funds ownership: 111.28%123.34% (+12%)

11% more funds holding

Funds holding: 174193 (+19)

25% less repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 77

67% less funds holding in top 10

Funds holding in top 10: 31 (-2)

86% less call options, than puts

Call options by funds: $305K | Put options by funds: $2.15M

Holders
193
Holders Change
+19
Holders Change %
+10.92%
% of All Funds
2.81%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.01%
New
33
Increased
58
Reduced
77
Closed
13
Calls
$305K
Puts
$2.15M
Net Calls
-$1.85M
Net Calls Change
-$790K

COLL Hedge Fund Activity: Q4 2023 in Review

193 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q4 2023, worth a combined $1.24B — up 43% from $865M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new COLL positions and 13 closed out — a net gain of 20 holders — while 58 added to existing stakes and 77 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $35.4M. The largest seller was BlackRock, cutting an estimated $11.4M.

  • 193 institutional investors held Collegium Pharmaceutical (COLL) as of Q4 2023, up from 174 in Q3 2023.
  • Funds reported $1.24B of Collegium Pharmaceutical stock for Q4 2023, up 43% quarter-over-quarter.
  • 33 funds opened new Collegium Pharmaceutical positions in Q4 2023 and 13 closed out, a net change of +20 holders.
  • The largest Collegium Pharmaceutical buyer in Q4 2023 was Morgan Stanley, an estimated $35.4M added.
  • The largest Collegium Pharmaceutical seller in Q4 2023 was BlackRock, an estimated $11.4M sold.

Based on aggregated 13F filings for Q4 2023.